SecBot SecBot
8-K ·Filed Jul 29, 2026

AXGN

Axogen, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0000805928-26-000091
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and accelerating Breast segment growth signal strong commercial execution and expanding market access. Monitor the Q3 earnings call for updates on Aetna coverage decision and prostate clinical development progress, which could provide further catalysts. The stock's 94% analyst bullish consensus suggests limited downside, but watch for margin pressure from continued investment in sales force expansion.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$41.37
T+0 close · Jul 29, 2026 · via day close
Latest settled
−11.34%
T+60 · $36.68
Vs SPY
−16.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $41.37entry
  2. T+1 · 4mo ago −0.05%α −1.72% · $41.35
  3. T+5 · 3mo ago +9.31%α +3.78% · $45.22
  4. T+20 · 3mo ago +24.68%α +19.66% · $51.58
  5. T+60 · 26d ago −11.34%α −16.07% · $36.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axogen reported Q2 2026 revenue of $69.7M (+23.1% YoY), slightly above the $67.1M consensus, and adjusted EPS of $0.12, in line with estimates. The company raised its full-year 2026 revenue guidance to at least $279M (24% growth), up from the prior $270M (20% growth) target, driven by accelerating Breast segment growth (>50% YoY) and expanding commercial insurance coverage. The stock is likely to react positively to the guidance raise and strong top-line momentum, though GAAP net loss widened to -$0.03/share vs +$0.01 a year ago, and adjusted EBITDA margin compressed to 12.1% from 16.3% due to increased investment in sales force and R&D.

Key Financial Metrics

EPS
$0.12
est $0.12 · 0.0%
Revenue
$69.7M
est $67.1M · +3.9% · +23.1% YoY
Rating
beat
Guidance
at least $279M
raised
Free Cash Flow
$4.1M
Gross Margin
72.7%

Key Facts

  • Q2 2026 revenue $69.7M, +23.1% YoY, vs consensus $67.1M
  • Adjusted EPS $0.12, in line with consensus
  • Full-year 2026 revenue guidance raised to at least $279M (24% growth), from prior $270M (20% growth)
  • Breast segment growth >50% YoY, driving product mix shift and gross margin compression to 72.7% from 74.2%
  • GAAP net loss -$1.5M (-$0.03/share) vs net income $0.6M ($0.01/share) in Q2 2025
  • Adjusted EBITDA $8.4M, margin 12.1% vs 16.3% a year ago
  • Cash, equivalents, restricted cash, and investments $113.4M; no debt outstanding
  • Avance commercial payer coverage ~86% of US covered lives; CMS proposed CY2027 payment rule increases nerve repair rates
  • Initiated Nerve-RESTORE Level 1 clinical study comparing Avance to autograft; REPOSE study published
  • Acquired minority stake in Trace Biosciences for nerve-specific imaging technology

Financial Impact

Revenue guidance raised by $9M at midpoint (from $270M to $279M), representing ~3.3% incremental upside vs prior outlook

revenuegross marginadjusted EBITDA marginfree cash flow

Risk Factors

  • Gross margin compression to 72.7% from 74.2% due to unfavorable product mix from faster-growing Breast segment
  • Adjusted EBITDA margin declined 420bps YoY to 12.1% as operating expenses grew faster than revenue (30.9% vs 23.1%)
  • GAAP net loss widened to -$1.5M from +$0.6M in prior year quarter
  • Dependence on continued commercial insurance coverage expansion for Avance; Aetna decision still pending
  • Prostate market development remains early stage with only 100+ procedures and 10+ active clinical sites

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000805928-26-000091
Exhibit: ex993q22026_axgnxcorpora.htm0000805928-26-000091
Exhibit: ex992axgn_q2earningsrele.htm0000805928-26-000091
Document: axgn-20260729.htm0000805928-26-000091
Document: 0000805928-26-000091-index-headers.html0000805928-26-000091
Document: 0000805928-26-000091-index.html0000805928-26-000091
Document: 0000805928-26-000091.txt0000805928-26-000091
8-K Data (Synthetic)0000805928-26-000091

Track record

19 reports on AXGN

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +32.04% at T+20 after the Oct 1, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $55.78 Now $55.38 +0.72% settles Dec 15
  2. Nov 9, 20267d ago 8-K Bullish 5/10 Entry $50.64 Now $55.38 +9.36% settles Dec 8
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $51.35 Now $55.38 +7.85% settles Dec 3
  4. Oct 28, 202619d ago 8-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $49.25 Now $55.38 +12.45% settles Nov 25
  6. Oct 2, 20266w ago SC 13G Neutral 4/10 Entry $37.22 to $49.37 Now $55.38 +48.79% ▲ +32.64% +35.11% vs SPY
  7. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $37.39 to $49.37 Now $55.38 +48.11% ▲ +32.04% +33.85% vs SPY
  8. Oct 1, 20266w ago Press Release Bullish 6/10 Entry $37.39 to $49.37 Now $55.38 +48.11% ▲ +32.04% +33.85% vs SPY
  9. Sep 10, 20269w ago 424B5 Mixed 6/10 Entry $42.16 to $36.13 Now $55.38 +31.36% ▼ −14.30% −16.17% vs SPY
  10. Sep 10, 20269w ago 8-K Bullish 7/10 Entry $41.85 to $36.18 Now $55.38 +32.33% ▼ −13.55% −15.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026